Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with Merck's (MRK) immuno-oncology agent Keytruda significantly improved ...

Trodelvy, in combination with Merck's immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results.

Gilead Sciences (NASDAQ:GILD) announced Friday that its antibody-drug conjugate Trodelvy reached the main goal compared to chemotherapy in a Phase 3 trial designed to test it as a first-line ...

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC IDEAYA Announces Further Gilead Sciences Clinical Study ...

The use of Trodelvy in MTAP-deletion UC is investigational, and the safety and efficacy of this use have not been established. A clinical program update on the IDE397 and Trodelvy combination is ...